Home LiteratureArticle Details
PMID: 19584284 Published · ppublish English Journal Article Research Support, N.I.H., Intramural

Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway.

Cancer research ·Vol. 69 ·No. 14 ·2009-07-15 ·Pages 5918-26

Bian Y, Terse A, Du J, Hall B, Molinolo A, Zhang P, Chen W, Flanders KC, Gutkind JS, Wakefield LM, Kulkarni AB

Abstract

The precise role of transforming growth factor (TGF)-beta signaling in head and neck squamous cell carcinoma (SCC) is not yet fully understood. Here, we report generation of an inducible head- and neck-specific knockout mouse model by crossing TGF-beta receptor I (Tgfbr1) floxed mice with K14-CreER(tam) mice. By applying tamoxifen to oral cavity of the mouse to induce Cre expression, we were able to conditionally delete Tgfbr1 in the mouse head and neck epithelia. On tumor induction with 7,12-dimethylbenz(a)anthracene (DMBA), 45% of Tgfbr1 conditional knockout (cKO) mice (n = 42) developed SCCs in the head and neck area starting from 16 weeks after treatment. However, no tumors were observed in the control littermates. A molecular analysis revealed an enhanced proliferation and loss of apoptosis in the basal layer of the head and neck epithelia of Tgfbr1 cKO mice 4 weeks after tamoxifen and DMBA treatment. The most notable finding of our study is that the phosphoinositide 3-kinase (PI3K)/Akt pathway was activated in SCCs that developed in the Tgfbr1 cKO mice on inactivation of TGF-beta signaling through Smad2/3 and DMBA treatment. These observations suggest that activation of Smad-independent pathways may contribute cooperatively with inactivation of Smad-dependent pathways to promote head and neck carcinogenesis in these mice. Our results revealed the critical role of the TGF-beta signaling pathway and its cross-talk with the PI3K/Akt pathway in suppressing head and neck carcinogenesis.

MeSH Terms
9,10-Dimethyl-1,2-benzanthracene/toxicity Animals Apoptosis Blotting, Western Carcinoma, Squamous Cell/genetics,metabolism,pathology Cell Cycle Cell Proliferation Enzyme Activation Epithelium/drug effects,metabolism,pathology Female Gene Deletion Head and Neck Neoplasms/genetics,metabolism,pathology Immunohistochemistry Male Mice Mice, Knockout Models, Biological Phosphatidylinositol 3-Kinases/metabolism Protein Serine-Threonine Kinases/genetics,metabolism Proto-Oncogene Proteins c-akt/metabolism Receptor, Transforming Growth Factor-beta Type I Receptors, Transforming Growth Factor beta/genetics,metabolism Signal Transduction Transforming Growth Factor beta/metabolism
Chemicals
Receptors, Transforming Growth Factor beta Transforming Growth Factor beta 9,10-Dimethyl-1,2-benzanthracene Protein Serine-Threonine Kinases Proto-Oncogene Proteins c-akt Receptor, Transforming Growth Factor-beta Type I Tgfbr1 protein, mouse
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Bian Yansong
Functional Genomics Section, Laboratory of Cell and Developmental Biology, National Institute of Dental and Craniofacial Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4330, USA.
Terse Anita
Du Juan
Hall Bradford
Molinolo Alfredo
Zhang Pin
Chen Wanjun
Flanders Kathleen C
Gutkind J Silvio
Wakefield Lalage M
Kulkarni Ashok B
References (49)
49 references, click to expand
  1. Somatic acquisition and signaling of TGFBR1*6A in cancer.
    JAMA. 2005 Oct 5;294(13):1634-46 PMID: 16204663
  2. TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma.
    Cell Cycle. 2007 Jun 1;6(11):1360-6 PMID: 17534148
  3. The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin.
    Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8551-6 PMID: 10411913
  4. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis.
    Cancer Res. 1999 Jul 15;59(14):3379-86 PMID: 10416598
  5. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors.
    EMBO J. 2002 Apr 2;21(7):1743-53 PMID: 11927558
  6. Cancer statistics, 2008.
    CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 PMID: 18287387
  7. The two faces of transforming growth factor beta in carcinogenesis.
    Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 PMID: 12861075
  8. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.
    Adv Immunol. 2006;90:1-50 PMID: 16730260
  9. Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia.
    Cancer Cell. 2007 Oct;12(4):313-27 PMID: 17936557
  10. Smad-dependent and Smad-independent pathways in TGF-beta family signalling.
    Nature. 2003 Oct 9;425(6958):577-84 PMID: 14534577
  11. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.
    N Engl J Med. 1991 Jan 3;324(1):1-8 PMID: 1701519
  12. The logic of TGFbeta signaling.
    FEBS Lett. 2006 May 22;580(12):2811-20 PMID: 16678165
  13. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity.
    Science. 2005 Mar 11;307(5715):1603-9 PMID: 15761148
  14. Specificity and versatility in tgf-beta signaling through Smads.
    Annu Rev Cell Dev Biol. 2005;21:659-93 PMID: 16212511
  15. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.
    Cell. 2005 May 6;121(3):335-48 PMID: 15882617
  16. Focus on head and neck cancer.
    Cancer Cell. 2004 Apr;5(4):311-6 PMID: 15093538
  17. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer.
    Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):41-58 PMID: 16310402
  18. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice.
    EMBO J. 2001 Apr 2;20(7):1663-73 PMID: 11285230
  19. Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma.
    Am J Otolaryngol. 2009 Mar-Apr;30(2):89-94 PMID: 19239949
  20. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model.
    Cancer Prev Res (Phila). 2009 Jan;2(1):27-36 PMID: 19139015
  21. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression.
    J Clin Invest. 2003 Oct;112(7):1116-24 PMID: 14523048
  22. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer.
    Nat Rev Cancer. 2006 Jul;6(7):506-20 PMID: 16794634
  23. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma.
    Genes Dev. 2006 May 15;20(10):1331-42 PMID: 16702406
  24. Dysregulated molecular networks in head and neck carcinogenesis.
    Oral Oncol. 2009 Apr-May;45(4-5):324-34 PMID: 18805044
  25. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia.
    Science. 2004 Feb 6;303(5659):848-51 PMID: 14764882
  26. Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis.
    Oncol Res. 2003;14(2):61-73 PMID: 14649540
  27. TGFbeta in Cancer.
    Cell. 2008 Jul 25;134(2):215-30 PMID: 18662538
  28. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression.
    Genes Dev. 2006 Nov 15;20(22):3147-60 PMID: 17114585
  29. Oral mucosal carcinogenesis in SENCAR mice.
    Anticancer Res. 2002 Sep-Oct;22(5):2733-40 PMID: 12529989
  30. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
    Cancer Res. 2008 Mar 15;68(6):1809-19 PMID: 18339861
  31. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis.
    Cancer Res. 1999 Jun 15;59(12):2861-8 PMID: 10383147
  32. Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
    Cancer Lett. 2007 Jan 8;245(1-2):163-70 PMID: 16478646
  33. Attenuated type II TGF-beta receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination.
    Int J Cancer. 2004 Jun 10;110(2):170-6 PMID: 15069677
  34. Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis.
    Adv Cancer Res. 2001;83:1-54 PMID: 11665716
  35. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.
    Clin Cancer Res. 1999 Jun;5(6):1369-79 PMID: 10389921
  36. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation.
    Cancer Res. 2004 Jul 1;64(13):4405-10 PMID: 15231647
  37. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
    Cancer Res. 2004 Jul 15;64(14):4687-92 PMID: 15256431
  38. Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers.
    Mutat Res. 2001 Aug 8;479(1-2):131-9 PMID: 11470488
  39. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer.
    Nature. 2006 Jun 22;441(7096):1015-9 PMID: 16791201
  40. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8430-5 PMID: 12808151
  41. Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells.
    Br J Cancer. 2004 Feb 23;90(4):822-32 PMID: 14970860
  42. Role of tissue stroma in cancer cell invasion.
    J Pathol. 2003 Jul;200(4):429-47 PMID: 12845611
  43. Molecular pathology of head-and-neck cancer.
    Int J Cancer. 2004 Nov 20;112(4):545-53 PMID: 15382034
  44. Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth.
    Mol Cell Biol. 2008 Nov;28(22):6889-902 PMID: 18794361
  45. PTEN: one gene, many syndromes.
    Hum Mutat. 2003 Sep;22(3):183-98 PMID: 12938083
  46. Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases.
    Int J Cancer. 2001 Sep 1;93(5):653-61 PMID: 11477574
  47. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells.
    Cancer Res. 2008 May 1;68(9):3152-60 PMID: 18451140
  48. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer.
    Prostate. 2002 Jun 1;51(4):268-75 PMID: 11987155
  49. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells.
    Nat Immunol. 2008 Jun;9(6):632-40 PMID: 18438410
Article Info
Journal
Cancer research
Abbr.
Cancer Res
ISSN
1538-7445
Published
2009-07-15
Epub
2009-00-07
Pages
5918-26
Language
English
Region
United States
NLM ID
2984705R
PMCID
PMC2758611
Subset
IM
Grants
Intramural NIH HHS · Z01 DE000698-09 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com